National Health (Pharmaceutical benefits – early supply) Amendment Instrument 2021 (No. 11) (Cth)

PB 119 of 2021

National Health (Pharmaceutical benefits – early supply) Amendment Instrument 2021
(No. 11)

National Health Act 1953

I, NIKOLAI TSYGANOV, Assistant Secretary (Acting), Pricing and PBS Policy Branch, Technology Assessment and Access Division, Department of Health, delegate of the Minister for Health and Aged Care, make this Instrument under subsection 84AAA(2) of the National Health Act 1953.

Dated   29 November 2021

NIKOLAI TSYGANOV

Assistant Secretary (Acting)

Pricing and PBS Policy Branch

Technology Assessment and Access Division

Department of Health

Contents

1......... Name............................................................................................................................... 1

2......... Commencement............................................................................................................... 1

3......... Authority......................................................................................................................... 1

4......... Schedules......................................................................................................................... 1

Schedule 1—Amendments  2

National Health (Pharmaceutical benefits—early supply) Instrument 2015
(PB 120 of 2015).   2

1. Name

(1)This instrument is the National Health (Pharmaceutical benefits – early supply) Amendment Instrument 2021 (No. 11).

(2)This Instrument may also be cited as PB 119 of 2021.

1. Commencement

(1)Each provision of this instrument specified in column 1 of the table commences, or is taken to have commenced, in accordance with column 2 of the table. Any other statement in column 2 has effect according to its terms.

Commencement information
Column 1	Column 2	Column 3
Provisions	Commencement	Date/Details
1. The whole of this instrument	1 December 2021	1 December 2021

Note:          This table relates only to the provisions of this instrument as originally made. It will not be amended to deal with any later amendments of this instrument.

(2)Any information in column 3 of the table is not part of this instrument. Information may be inserted in this column, or information in it may be edited, in any published version of this instrument.

1. Authority

This instrument is made under subsection 84AAA(2) of the National Health Act 1953.

4        Schedules

Each instrument that is specified in a Schedule to this instrument is amended or repealed as set out in the applicable items in the Schedule concerned, and any other item in a Schedule to this instrument has effect according to its terms.

Schedule 1—Amendments

National Health (Pharmaceutical benefits—early supply) Instrument 2015 (PB 120 of 2015)

1. Schedule 1, omit entry for Dalteparin

1. Schedule 1, after entry for Lamotrigine in the form Tablet 200 mg

insert:

Lanadelumab Injection 300 mg in 2 mL single use pre-filled syringe 20 1 5

1. Schedule 1, entry for Mesalazine in the form Sachet containing prolonged release granules, 1 g per sachet

omit:

20 120 5

1. Schedule 1, entry for Ribavirin

insert as first entry:

Tablet 200 mg 20 200 2

1. Schedule 1, after entry for Riluzole

insert:

Ripretinib Tablet 50 mg 20 90 1

1. Schedule 1, entry for Venetoclax

substitute:

Venetoclax	Tablet 100 mg	20	120	2
20	120	4
20	120	5